- Home
- PRFX vs THAR Comparison
PRFX vs THAR Comparison
Compare PRFX & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- THAR
- Stock Information
- Founded
- PRFX 2007
- THAR 2017
- Country
- PRFX Israel
- THAR United States
- Employees
- PRFX 6
- THAR N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- THAR Health Care
- Exchange
- PRFX Nasdaq
- THAR Nasdaq
- Market Cap
- PRFX 3.3M
- THAR 5.5M
- IPO Year
- PRFX 2020
- THAR 2022
- Fundamental
- Price
- PRFX $1.69
- THAR $4.72
- Analyst Decision
- PRFX Hold
- THAR Strong Buy
- Analyst Count
- PRFX 1
- THAR 1
- Target Price
- PRFX N/A
- THAR $17.00
- AVG Volume (30 Days)
- PRFX 8.5M
- THAR 22.9M
- Earning Date
- PRFX 08-29-2025
- THAR 08-14-2025
- Dividend Yield
- PRFX N/A
- THAR N/A
- EPS Growth
- PRFX N/A
- THAR N/A
- EPS
- PRFX N/A
- THAR N/A
- Revenue
- PRFX N/A
- THAR N/A
- Revenue This Year
- PRFX N/A
- THAR N/A
- Revenue Next Year
- PRFX N/A
- THAR N/A
- P/E Ratio
- PRFX N/A
- THAR N/A
- Revenue Growth
- PRFX N/A
- THAR N/A
- 52 Week Low
- PRFX $1.25
- THAR $0.95
- 52 Week High
- PRFX $16.63
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- PRFX 54.34
- THAR 83.95
- Support Level
- PRFX $1.57
- THAR $1.08
- Resistance Level
- PRFX $3.59
- THAR $6.09
- Average True Range (ATR)
- PRFX 0.22
- THAR 0.52
- MACD
- PRFX 0.05
- THAR 0.40
- Stochastic Oscillator
- PRFX 18.80
- THAR 72.65
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.